Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSP1273 DDI Study with Warfarin and Midazolam
NCT05942365Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- Jun 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of anlatrelvir in Influenza A (IAV), sponsored by Raynovent Biotech. Primary endpoints: S-warfarin Maximum Plasma Concentration, Midazolam Maximum Plasma Concentration and 2 more. Started Jun 2023; status: completed.
02
Drugs
anlatrelvir
03
Conditions
Influenza A (IAV)
Beyond the preview
Go deeper on NCT05942365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05942365.